Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | CBFB | Q13951 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2812775 | 0.95 | NAMPT (0.34) | NAMPTTAAR1MAPTESR1CYP19A1 | |
| SCHEMBL2806216 | 0.83 | TAAR1 (0.33) | TAAR1DAOCYP2C8HCAR2 | |
| SCHEMBL2807581 | 0.79 | KMT2A (0.33) | TAAR1MAPTKDM4ELMNA | |
| SCHEMBL148755 | 0.78 | SHBG (0.48) | TAAR1MAPTESR1ESR2SHBG | |
| SCHEMBL29741490 | 0.78 | SHBG (0.48) | TAAR1MAPTESR1ESR2SHBG | |
| SCHEMBL3080203 | 0.77 | TSHR (0.44) | MAPTCYP2C8KDM4E | |
| SCHEMBL2810557 | 0.76 | KDM4E (0.41) | TAAR1MAPTKDM4ELMNA | |
| SCHEMBL27973124 | 0.75 | ALDH1A1 (0.41) | KDM4E | |
| SCHEMBL1229227 | 0.74 | REN (0.38) | MAPTHSD17B10DAOHCAR2KDM4E | |
| SCHEMBL661713 | 0.74 | CYP4F2 (0.44) | DAOKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362040-B2 | 4-phenylpiperidine derivatives as renin inhibitors | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-20100240679-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-7754727-B2 | 4-phenylpiperidine derivatives as renin inhibitors | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-20080269255-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20070078164-A1 | 4-Phenylpiperidine derivatives as renin inhibitors | SEDRANI RICHARD | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269255-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | REN, AGTR1, ACE | NAMPT 3894/4885TAAR1 1257/4885MAPT 731/4885 |
| US-20100240679-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | REN, AGTR1, ACE | NAMPT 3783/4885TAAR1 1517/4885MAPT 625/4885 |
| US-20070078164-A1 | 4-Phenylpiperidine derivatives as renin inhibitors | REN, AGTR1, ACE | NAMPT 3783/4885TAAR1 1517/4885MAPT 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.